Next Article in Journal
Ginseng Metabolites on Cancer Chemoprevention: An Angiogenesis Link?
Previous Article in Journal
Metabolomic Approaches in Cancer Epidemiology
Article Menu

Export Article

Open AccessReview
Diseases 2015, 3(3), 176-192;

MOGAT2: A New Therapeutic Target for Metabolic Syndrome

Institute of Metabolic Disorders, Genesis Biotechnology Group, Hamilton, NJ 08691, USA
Authors to whom correspondence should be addressed.
Academic Editor: Maurizio Battino
Received: 29 June 2015 / Revised: 13 August 2015 / Accepted: 17 August 2015 / Published: 28 August 2015
Full-Text   |   PDF [900 KB, uploaded 28 August 2015]   |  


Metabolic syndrome is an ever-increasing health problem among the world’s population. It is a group of intertwined maladies that includes obesity, hypertriglyceridemia, hypertension, nonalcoholic fatty liver disease (NAFLD), and diabetes mellitus type II (T2D). There is a direct correlation between high triacylglycerol (triglyceride; TAG) level and severity of metabolic syndrome. Thus, controlling the synthesis of TAG will have a great impact on overall systemic lipid metabolism and thus metabolic syndrome progression. The Acyl-CoA: monoacylglycerolacyltransferase (MGAT) family has three members (MGAT1, -2, and -3) that catalyze the first step in TAG production, conversion of monoacylglycerol (MAG) to diacylglycerol (DAG). TAG is then directly synthesized from DAG by a Acyl-CoA: diacylglycerolacyltransferase (DGAT). The conversion of MAG → DAG → TAG is the major pathway for the production of TAG in the small intestine, and produces TAG to a lesser extent in the liver. Transgenic and pharmacological studies in mice have demonstrated the beneficial effects of MGAT inhibition as a therapy for treating several metabolic diseases, including obesity, insulin resistance, T2D, and NAFLD. In this review, the significance of several properties of MGAT physiology, including tissue expression pattern and its relationship to overall TAG metabolism, enzymatic biochemical properties and their effects on drug discovery, and finally what is the current knowledge about MGAT small molecule inhibitors and their efficacy will be discussed. Overall, this review highlights the therapeutic potential of inhibiting MGAT for lowering TAG synthesis and whether this avenue of drug discovery warrants further clinical investigation. View Full-Text
Keywords: triglyceride; metabolic disorders; obesity; acyltransferases triglyceride; metabolic disorders; obesity; acyltransferases

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Yang, M.; Nickels, J.T., Jr. MOGAT2: A New Therapeutic Target for Metabolic Syndrome. Diseases 2015, 3, 176-192.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top